PACBPacific Biosciences of California, Inc.
Price
+64%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, a flag to check, the market undecided.
Charts
As reported to the SEC, without any scoring.
Pacific Biosciences of California, Inc. (PACB) reported revenue of $39M in Q2 2026 (quarter ended Jun 30, 2026), down 1.9% from the same quarter a year earlier. That came with a gross margin of 32% and net loss of $45M. For the full year FY2025, revenue was $160M (+3.9% year on year) and net income −$546M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026On July 30, 2026, the Board of Directors (the “Board”) of the Company approved a restructuring plan to continue to better align the Company’s organizational structure and resources with its strategic initiatives.Earnings release · Form 8-K
- Jul 9, 2026On July 8, 2026, Christopher M. Smith, a member of the board of directors (the “Board”) of Pacific Biosciences of California, Inc. (the “Company”), notified the Company of his resignation from the Board, effective immediately.Director or officer change · Form 8-K
- Jun 4, 2026On April 21, 2026, the board of directors (the "Board") of Pacific Biosciences of California, Inc. (the “Company”), at the recommendation of the compensation committee of the Board, approved an amendment (the “Amendment”) to the Company’s 2020 Equity Incentive Plan (the “2020 Plan”), subject to stockholder approval …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.